25.91 -0.63 (-2.37%) | 05-02 15:16 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 36.11 | 1-year : | 42.18 |
Resists | First : | 30.92 | Second : | 36.11 |
Pivot price | 26.24 | |||
Supports | First : | 21.68 | Second : | 15.97 |
MAs | MA(5) : | 27.42 | MA(20) : | 25.09 |
MA(100) : | 15.75 | MA(250) : | 17.33 | |
MACD | MACD : | 2.1 | Signal : | 2.3 |
%K %D | K(14,3) : | 56.5 | D(3) : | 65.6 |
RSI | RSI(14): 58.1 | |||
52-week | High : | 30.92 | Low : | 8.24 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ QTTB ] has closed above bottom band by 48.6%. Bollinger Bands are 83.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 22 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 27.23 - 27.4 | 27.4 - 27.52 |
Low: | 25.51 - 25.71 | 25.71 - 25.86 |
Close: | 26.26 - 26.57 | 26.57 - 26.79 |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Tue, 23 Apr 2024
Q32 Bio executive sells shares worth $1,815 By Investing.com - Investing.com Nigeria
Wed, 03 Apr 2024
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer - citybiz
Tue, 02 Apr 2024
Healthcare Stocks Moving Up and Down Tuesday: NXL, CARM, QTTB, ACB, VERV, TFFP, CDIO, PTPI - InvestorsObserver
Tue, 02 Apr 2024
Piper Sandler updates price target on Q32 Bio stock, bullish on lead assets - Investing.com
Wed, 27 Mar 2024
Homology Medicines Transforms into Q32 Bio Inc. Post-Merger - TipRanks.com - TipRanks
Tue, 26 Mar 2024
QTTB Stock Price and Chart — NASDAQ:QTTB — TradingView - TradingView
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 12 (M) |
Shares Float | 5 (M) |
Held by Insiders | 2.5 (%) |
Held by Institutions | 65 (%) |
Shares Short | 10 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 176 % |
Return on Assets (ttm) | -55.5 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -0.56 |
EBITDA (p.s.) | -4.01 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -19 (M) |
Levered Free Cash Flow | -41 (M) |
PE Ratio | 0 |
PEG Ratio | 0.3 |
Price to Book value | 0 |
Price to Sales | -46.9 |
Price to Cash Flow | -16.7 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |